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ABSTRACT

Pharmaceutical compounds comprising bridged nicotine
analogs of N-octylnicotinium iodide (NONI) having selec
tive antagonist properties at (x3[32-containing nicotinic
receptor subtypes, and compositions containing these com
pounds. The compounds and compositions are used to treat
central nervous system pathologies.

36 Claims, No Drawings
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BRIDGED NICOTINE COMPOUNDS FOR
USE IN THE TREATMENT OF CNS
PATHOLOGIES

The structural and functional diversity of CNS nicotinic
receptors has stimulated a great deal of interest in develop

ing novel, subtype-selective agonists. Some of these ago
nists are currently being evaluated in clinical trials for

RELATED APPLICATION

cognitive enhancement and neuroprotective effects poten

This application claims priority from US. Provisional
Patent Application Serial No. 60/228,76, ?led Aug. 30,

tially bene?cial for diseases such as AlZheimer’s and Par
kinson’s Disease. Surprisingly, little attention a has been

focused on developing subtype-selective antagonists for
neuronal nicotinic receptors.

2000, incorporated herein by reference.
FIELD OF THE INVENTION

10

N-octylnicotinium iodide (NONI) that have selective
antagonist properties at (x3[32-containing nicotinic receptor
subtypes and to a method of using such compounds to treat
central nervous system pathologies. The present invention

A class pyridino N-substituted nicotine analogs having
formula (II) beloW are knoWn antagonists that inhibit nico
tine evoked [3H]DA release from dopaminergic nerve ter
minals in the brain. The abbreviated nomenclature is given

This invention relates to bridged nicotine analogs of

in parentheses.
15

also relates to pharmaceutical compositions containing these
compounds, as Well as various uses thereof.
0"‘

BACKGROUND OF THE INVENTION

Formula (I) beloW shoWs the structure of S-(—)-nicotine
(NIC), Which activates neuronal nicotinic receptors evoking
release of dopamine (DA) from presynaptic terminals in the

l

20

\
/ \\\

CH3

N

S- (—)nicotine (NIC)

central nervous system (CNS). NIC is a legal substance of
dependence that produces many of its effects on the CNS,
some of Which may be considered to be bene?cial, e.g.,

mood elevation, arousal and learning and memory enhance
ment. NIC produces its effect by binding to a family of

l

ligand-gated ion channels, stimulation by acetylcholine

9

(ACh) or NIC causes the ion channel to open, and cations to

?ux With a resulting rapid (in msec) depolariZation of the

I
30

target cell.
Over the last 12 years, there has been a substantial
increase in studies on brain nicotinic receptors. These nico

tinic receptors are composed of four subunit domains: 2a, [3,

35

y and 6 or e. Neuronal nicotinic receptors are composed of
only tWo subunits, 0t and [3 and are believed to assemble With

the general stoichiometry of 20. and 3[3. Eight subtypes of
the ot subunit (a2 to Q9) and three subtypes of the [3 unit ([32
to [34) are found in CNS. The most common nicotinic

40

receptor species in the brain is composed of tWo (x4 and

three [32 subunits, i.e., (x4[32. These subunits display
different, but overlapping, patterns of expression in the
brain.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to

l

R
a) R = b) R = c) R = d) R = e) R = -

(CH2)7CH3 (NONI)
(CH2)8CH3 (NNNI)
(CH2)9CH3 (NDNI)
(CH2)10CH3 (NUNI)
(CH2)11CH3 (NDDNI)

These compounds are useful in the treatment of nicotine
abuse, smoking cessation therapy, as an antidote for nicotine
intoxication, treatment of cognitive disorders such as AlZhe
imer’s disease and for the treatment of Parkinson’s disease.
The compounds and their method of use Were the subject of
US. Pat. No. 5,691,365, issued Nov. 25, 1997. The content
The invention disclosed herein is directed to another neW

45

class of efficacious and subtype-selective nicotinic antago
nists at nicotinic receptors in the CNS. These compounds

comprise bridged nicotine analogs of NONI.

sequence at the subunit level and from the multiple combi
nations of assemblies of subunits into functional receptor

SUMMARY OF THE INVENTION

The present invention provides; for bridged nicotine ana

proteins afford Wide diversity of pharmacological speci?c

logs of N-octylnicotinium iodide (NONI) compounds hav

ity.

ing potent and selective antagonistic activity at neuronal

nicotinic receptor subtypes. The compounds competitively
55

[3H]NIC appears to label the same sites in the brain as

[3H]ACh. It has been estimated that over 90% of [3H]NIC

inhibit CNS acting nicotinic receptor agonists that are acting
as putative 0L3[32 neuronal nicotinic receptor in the CNS.
A preferred embodiment of the invention provides for a
method of antagoniZing the nicotinic receptor comprising
administering of a pharmaceutically effective amount of a

binding in the brain is due to association With a receptor that

is composed of (X4 and [32 subunits. Also, nicotinic receptor

TCH3

N

of this patent is incorporated herein by reference.

be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid

In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many such studies.

@/

60

subtypes can be studied using an assay such as NIC-evoked

compound of the invention.
Still another embodiment the invention provides a method

[3H]DA release from rat straital slices. Nicotinic receptors

for the treatment of psychostimulant abuse (including nico

are located in the cell body and terminal areas of the

tine abuse, amphetamine abuse, methamphetamine abuse,

nigrostriatal system. NIC facilitates DA release from striatal
nerve terminals. Studies strongly suggest that the [3H]DA
release assay is useful to probe the (x3[32-containing subtype
of the nicotinic receptor.

alcohol abuse and cocaine abuse), as smoking cessation
65

therapy, as an antidote for nicotine intoxication comprising
administering of a pharmaceutically effective amount of a

compound according to the invention, as a therapeutic agent

US 6,503,922 B2
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3
for the treatment of pathologies of the GI tract, including
irritable bowel syndrome, colitis and related disorders.

the backbone thereof, or a C(O), O, N(Y1), C(S), S,
S(O) or S(O)2 containing alkene moiety, Wherein Y1 is
hydrogen or loWer alkyl or aryl;

This invention further provides a method of treatment of
CNS disorders associated With the alteration of normal

neurotransmitter release in the brain, including conditions

5

methyl, ethyl, isopropyl or isobutyl) or an aromatic

such as AlZheimer’s disease as Well as other types of

group-containing species;

dementia, Parkinson’s disease, cognitive dysfunction

R2 is selected from hydrogen or loWer alkyl;
R3, R4 and R5 are each independently selected from

(including disorders of attention, focus and concentration),
attention de?cit syndrome, affective disorders, mood and
emotional disorders such as depression, panic anXiety and

psychosis, Tourette’s syndrome, schiZophrenia, eating dis
orders and the control of pain comprising administering of
a pharmaceutically effective amount of a compound accord

ing to the invention.
The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

15

folloWing detailed description and ?gures, Wherein only the
preferred embodiments of the invention are shoWn and

hydrogen; alkyl; substituted alkyl; cycloalkyl; substi
tuted cycloalkyl; alkenyl; substituted alkenyl; alkynyl;
substituted alkynyl; aryl; substituted aryl; alkylaryl;
substituted alkylaryl; arylalkyl; substituted arylalkyl;
arylalkenyl; substituted arylalkenyl; arylalkynyl; sub
stituted arylalkynyl; heterocyclic; substituted heterocy
clic; tri?uoromethyl; halogen; cyano; nitro; S(O)Y2,
S(O)2Y2, S(O)2OY2 or S(O)2NHY2, Wherein each Y2
is independently hydrogen, loWer alkyl, alkenyl, alky
nyl or aryl, provided, hoWever, that When R3, R4 or R5
is S(O)Y2, Y2 is not hydrogen, and further provided

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

that When Y2 is alkenyl or alkynyl, the site of unsat
uration is not conjugated With a heteroatom; C(O)Y3,
Wherein Y3 is selected from hydrogen, alkyl, substi

the invention.
25

DETAILED DESCRIPTION OF THE
INVENTION

R1 is selected from hydrogen, loWer alkyl (e.g., C1—C1O
alkyl, preferably C1—C6 alkyl, and more preferably

The present invention provides, novel bridged-ring com
pounds corresponding to the schematic structure formulas

tuted alkyl, alkoXy, alkylamino, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted
aryl, aryloXy, arylamino, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, substituted heterocyclic or

tri?uoromethyl, provided, hoWever, that the carbonyl

III and IV beloW:

functionality is not conjugated With an alkenyl or
III

35

alkynyl functionality; OY4 or N(Y“)2 Wherein each Y4
is independently selected from hydrogen, alkyl, substi
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl,
substituted aryl, alkylaryl, substituted alkylaryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted

arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, substituted heterocyclic, acyl,
tri?uoromethyl, alkylsulfonyl or arylsulfonyl,
provided, hoWever, that the OY4 or N(Y“)2 function
ality is not conjugated With an alkenyl or alkynyl

functionality; SY5 Wherein Y5 is selected from
45

hydrogen, alkyl, substituted alkyl, cycloalkyl, substi
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub
stituted arylalkynyl, heterocyclic, substituted heterocy
clic or tri?uoromethyl, provided, hoWever, that the SY5
functionality is not conjugated With an alkenyl or

alkynyl functionality;
R6 is selected from alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl,
Wherein
A is a 1, 2 or 3 atom bridging species selected from

55

straight chain or branched chain alkylene moiety hav

erocyclic or substituted heterocyclic; and

ing up to 3 atoms in the backbone thereof, or a

substituted alkenylene moiety having up to 3 atoms in
the backbone thereof, or a C(O), O, C(S), S, S(O) or

aO

S(O)2 containing alkylene moiety, provided hoWever,
that any heteroatom contained in Ais separated from N
by at least one carbon atom;
B is a 1, 2 or 3 atom bridging species selected from
straight chain or branched chain alkylene moiety hav

alkynyl, substituted alkynyl, aryl, substituted aryl,
arylalkyl, substituted arylalkyl, arylalkenyl, substituted
arylalkenyl, arylalkynyl, substituted arylalkynyl, het
X is selected from chlorine, bromine, iodine, HSO4,
1/2SO2, CH3SO3, p-TsO or CF3SO3.
The junction betWeen rings a and b can be either cis or

trans geometry. The present invention includes all possible
diastereomers and all enantiomeric forms as Well as racemic

mixtures. The compounds can be separated into substan
65

tially optically pure compounds. The compounds of the

ing up to 3 atoms in the backbone thereof, or a

invention are nicotinic receptor antagonists. They inhibit

substituted alkenylene moiety having up to 3 atoms in

NIC-evoked [3H]-DA release and inhibit [3H]-NIC binding.

US 6,503,922 B2
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suf?cient to provide circulating concentrations high

It is preferred that A is either CH2 or CHZCHZ; B is CH2,
CHZCH2 or N(Y1) Where Y1 is either hydrogen or methyl;

enough to impart a bene?cial effect on the recipient
thereof. Such levels typically fall in the range of about
0.001 up to about 100 mg/kg/day, With levels in the
range of about 0.05 up to about 10 mg/kg/day being

R1 is a C1—C1O alkyl or more preferably a C1—C6 alkyl or
even more preferably a C —C4 alkyl such as a methyl, ethyl,

isopropyl or isobutyl; R is hydrogen; R3, R4 and R5 are
individually selected from the group consisting of hydrogen,
halogen, alkyl and alkanoyl; R6 is a C4—C19 unbranched

preferred.
The novel compounds of this invention are substantially

optically pure.

alkyl; and X is iodine.
As employed herein, the meaning of the aforementioned

The bridged nicotine analogs of NONI include com
pounds having formulas V and VI. The abbreviated nomen

terms are de?ned as folloWs:

clature is given in parentheses.

“loWer alkyl” refers to straight or branched chain alkyl
radicals having in the range of 1 up to 4 carbon atoms;
“alkyl” refers to straight or branched chain alkyl radicals

V

having in the range of 1 up to 19 carbon atoms and

“substituted alkyl” refers to alkyl radicals further bear

15

ing one or more substituents such as hydroXy, alkoXy

(of a loWer alkyl group), mercapto (of a loWer alkyl

group), aryl, heterocyclic, halogen, tri?uoromethyl,
cyano, nitro, amino, carboXyl, carbanate, sulfonyl,
sulfonamide, and the like.
“cycloalkyl” refers to cyclic ring-containing radicals con

20

taining in the range of 3 up to 8 carbon atoms and

“substituted cycloalkyl” refers to cycloalkyl radicals
further bearing one or more substituent as set forth

above;

25

“alkenyl” refers to straight or branched chain hydrocarbyl
radicals having at least one carbon-carbon double bond,

a) R = '
b) R = c) R = d) R = '
6) R = —

(CH2)7CH3 (AC0)
(CH2)8CH3 (ACN)
(CH2)9CH3 (ACD)
(CH2)10CH3 (ACU)
(CH2)11CH3 (ACDD)

VI

and having in the range of 2 up to 19 carbon atoms and

“substituted alkenyl” refers to alkenyl radicals further
bearing one or more substituents as set forth above;

30

“alkynyl” refers to straight or branched chain hydrocarbyl
radicals having at least one carbon-carbon triple bond,
and having in the range of 2 up to 19 carbon atoms and
“substituted alkynyl” refers to alkynyl radicals further
bearing one or more substituents as set forth above;

35

“aryl” refers to aromatic radicals having in the range of 6
up to 24 carbon atoms and “substituted aryl” refers to
aryl radicals further bearing one or more substituents as

set forth above;

“alkylaryl” refers to alkyl-substituted aryl radicals and
“substituted alkylaryl” refers to alkylaryl radicals fur

40

ther bearing one or more substituents as set forth above;

45

not limited to, the folloWing speci?c compounds:

and “substituted arylalkenyl” refers to arylalkenyl radi
cals further bearing one or more substituents as set

forth above;
“arylalkynyl” refers to aryl-substituted alkynyl radicals
and “substituted arylalkynyl” refers to arylalkynyl radi
cals further bearing one or more substituents as set
55

bearing one or more substituents as set forth above;

“heterocyclic” refers to cyclic radicals containing one
or more heteroatoms as part of the ring structure, and

having in the range of, 3 up to 24 carbon atoms and

60

“substituted heterocyclic” refers to heterocyclic radi
cals further bearing one or more substituents as set

forth above; “acyl” refers to alkyl-carbonyl species;
“halogen” refers to ?uoride, chloride, bromide or iodide

radicals; and
“an effective amount”, When used in reference to com

pounds of the invention, refers to doses of compound

inhibit dopamine release induced by nicotine in superfused
rat striatal slice preparations, While exhibiting Weak insig
ni?cant inhibition of [3H]-nicotine and [3H]-MLAbinding to
rat striatal membranes. These compounds include, but are

“arylalkenyl” refers to aryl-substituted alkenyl radicals

forth above;
“aroyl” refers to aryl-substituted species such as benZoyl
and “substituted aroyl” refers to aroyl radicals further

(CH2)7CH3 (BCO)
(CH2)8CH3 (BCN)
(CH2)9CH3 (BCD)
(CH2)10CH3 (BCU)
(CH2)11CH3 (BCDD)

These compounds potently, competitively and selectively

ther bearing one or more substituents as set forth above;

“arylalkyl” refers to aryl-substituted alkyl radicals and
“substituted arylalkyl” refers to arylalkyl radicals fur

a) R = b) R = c) R = d) R = '
6) R = —

65

cis-1-methyl-8-octyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[3,2-h]isoquinolin-8-ium iodide (ACO),
cis-1-methyl-8-nonyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[3,2-h]isoquinolin-8-ium iodide (ACN),
cis-8-decyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[3,2-h]isoquinolin-8-ium iodide (ACD),
cis-1-methyl-8-undecyl-2,3,3a,4,5,9b-heXahydro-1H
pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACU),
cis-8-dodecyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H
pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACDD).
cis-1-methyl-6-octyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[2,3-f]isoquinolin-6-ium iodide (BCO),
cis-1-methyl-6-nonyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[2,3-f]isoquinolin-6-ium iodide (BCN),
cis-6-decyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo
[2,3-f]isoquinolin-6-ium iodide (BCD),
cis-1-methyl-6-undecyl-2,3,3a,4,5,9b-heXahydro-1H
pyrrolo[2,3-f]isoquinolin-6-ium iodide (ECU), and

cis-6-dodecyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H
pyrrolo[2,3-f]isoquinolin-6-ium iodide (BCDD).

US 6,503,922 B2
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These compounds can be prepared from corresponding
free bases by reaction With an appropriate alkyl iodide using
techniques knoWn to those skilled in the art of organic
synthesis. The requisite free bases can be synthesiZed using
the techniques set forth by Chavdarian et al., J Org. Chem.
48:492 (1983), Glassco et al.,J. Med. Chem. 36:3381 (1993)
and Vernier et al., Bioorg. Med. Chem. Lett. 812173 (1998).

mmol) in AcOH (2 ml) Was added 1-iododecane (342 mg,
1.28 mmol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 130 mg (67%) of cis-8-decyl-1-methyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

The invention Will noW be described in greater detail by

reference to the following non-limiting examples.

(ACD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16
10

EXAMPLE 1

Preparation of cis-1-Methyl-8-octyl-2,3,3a,4,5,9b

hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium
iodide (ACO)

15

To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b

22.7, 14.2.

hexahydro-1H-pyrrolo[3,2-h]isoquinoline (100 mg, 0.53
mmol) in AcOH (2 ml) Was added 1-iodooctane (383 mg,
1.59 mmol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated
aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether

afforded 155 mg (68%) of cis-1-methyl-8-octyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

EXAMPLE 4
20

EXAMPLE 2

iodide (ACU)
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b
25

30

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 210 mg (70%) of cis-1-methyl-8-undecyl-2,3,3a,4,

5,9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide
(ACU) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16
35

hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium
iodide (ACN)
40

To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b

hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64
mmol) in AcOH (2 ml) Was added 1-iodononane (488 mg,

(1H, s, C9-H), 9.07 (1H, d, J6.0 HZ, C7-H), 7.81 (1H, d, J6.0
HZ, C6-H), 4.82 (2H, m. pyCHZ), 3.44 (1H, d, J8.4 HZ,
C9b-H), 2.29 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH),
1.95 (2H, m, pyCHZCHZ), 1.00—1.40 (16H, m, 8><CH2), 0.76
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3)
6161.5, 143.2, 142.4, 138.8, 127.5, 63.1, 61.0, 55.7, 41.0,
35.6, 32.0, 31.8, 30.0, 29.51, 29.48, 29.4, 29.2, 29.1, 28.1,
27.3, 26.0, 22.6, 14.1.
EXAMPLE 5

45

Preparation of cis-8-Dodecyl-1-methyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 222 mg (79%) of cis-1-methyl-8-nonyl-2,3,3a,4,5,

iodide (ACDD)
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b

9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64
mmol) in AcOH (2 ml) Was added 1-iodoundecane (569 mg,

(ACN) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.05

(1H, s, C9-H), 9.03 (1H, d, J6.0 HZ, C7-H), 7.81 (1H, d, J6.0
HZ, C6-H), 4.88 (2H, m. pyCHZ), 3.47 (1H, d, J8.7 HZ,
C9b-H), 2.36 (3H, s, NCH3), 1.60—3.10 (9H, m, CH2+CH),
2.00 (2H, m, pyCHZCHZ), 1.10—1.50 (12H, m, 6><CH2), 0.83
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3)
6161.7, 143.4, 142.5, 139.2, 127.5, 63.5, 61.5, 55.9, 41.3,
35.9, 32.1, 32.0, 30.3, 29.5, 29.3, 29.2, 28.2, 27.6, 26.2, 22.8,

hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64
mmol) in AcOH (2 ml) Was added 1-iodoundecane (542 mg,
1.92 mmol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

Preparation of cis-1-Methyl-8-nonyl-2,3,3a,4,5,9b

1.92 mmol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

Preparation of cis-1-Methyl-8-undecyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium

(ACO) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16

(1H, s, C9-H), 9.03 (1H, d, J6.0 HZ, C7-H), 7.82 (1H, d, J6.0
HZ, C6-H), 4.86 (2H, m. pyCHZ), 3.66 (1H, d, J8.4 HZ,
C9b-H), 2.43 (3H, s, NCH3), 1.55—3.20 (9H, m, CH2+CH),
1.99 (2H, m, pyCHZCHZ), 1.00—1.50 (10H, m, 5><CH2), 0.81
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3)
6161.8, 143.5, 142.5, 138.2, 127.6, 63.4, 61.4, 55.8, 41.2,
35.8, 32.1, 31.8, 30.0, 29.2><2, 27.8, 27.6, 26.2, 22.7, 14.2.

(1H, s, C9-H), 9.14 (1H, d, J5.4 HZ, C7-H), 7.82 (1H, d, J6.0
HZ, C6-H), 4.85 (2H, m. pyCHZ), 3.43 (1H, d, J8.4 HZ,
C9b-H), 2.30 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH),
1.96 (2H, m, pyCHZCHZ), 1.00—1.40 (14H, m, 7><CH2), 0.78
(3H, t, J6.9 HZ, CHZCHB); 13C NMR (75 MHZ, CDCl3)
6161.5, 143.4, 142.7, 138.9, 127.5, 63.3, 61.2, 55.8, 41.0,
35.7, 32.1, 31.9, 30.1, 29.5, 29.4, 29.3, 29.2, 28.2, 27.3, 26.1,

1.92 mmol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated
55

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 205 mg (66%) of cis-8-dodecyl-1-methyl-2,3,3a,4,

5,9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

14.2.

(ACDD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.08
60

EXAMPLE 3

Preparation of cis-8-Decyl-1-methyl-2,3,3a,4,5,9b

hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium
iodide (ACD)
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b

hexahydro-1H-pyrrolo[3,2-h]isoquinoline (80 mg, 0.43

65

(1H, s, C9-H), 9.02 (1H, d, J6.3 HZ, C7-H), 7.79 (1H, d, J6.3
HZ, C6-H), 4.90 (2H, m. pyCHZ), 3.48 (1H, d, J8.4 HZ,
C9b-H), 2.36 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH),
2.00 (2H, m, pyCHZCHZ), 1.10—1.40 (18H, m, 9><CH2), 0.85
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3)
6161.5, 143.3, 142.5, 138.8, 127.5, 63.1, 61.0, 55.7, 41.0,
35.6, 32.0, 31.9, 30.0, 29.6><2, 29.5, 29.4, 29.3, 29.1, 28.1,
27.3, 26.0, 22.7, 14.1.

US 6,503,922 B2
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EXAMPLE 6

J81 HZ, C9b-H), 2.23 (3H, s, NCH3), 1.64—3.30 (11H, rn,
CH2+CH), 1.10_1.50 (14H, rn, 7><CH2), 0.80 (3H, 1, J6.6 HZ,

Preparation of cis-1-Methyl-6-octyl-2,3,3a,4,5,9b

CH2CH3); 13c NMR (75 MHZ, CDC13) 6156.9, 145.8,
144.6, 138.8, 125.3, 66.2, 58.9, 55.5, 40.5, 35.3, 31.9, 30.9,

hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn
iodide (BCO)

29.6, 29.5, 29.4, 29.3, 29.2, 28.2, 26.3, 24.6, 22.7, 14.1.

To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b

EXAMPLE 9

hexahydro-1H-pyrrolo[2,3-f]isoquinoline (120 mg, 0.64
rnrnol) in AcOH (2 ml) Was added 1-iodooctane (460 mg,
1.92 rnrnol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated
aqueous NaHCO3, Water and brine successively and dried.

Evaporation of the solvent folloWed by titration With ether
afforded 155 mg (57%) of cis-1-rnethyl-6-octyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide

Preparation of cis-1-Methyl-6-undecyl-2,3,3a,4,5,
10

iodide (BCU)
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b
15

(BCO) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.38

(1H, d, J6.0 HZ, C7-H), 8.20 (1H, d, J7.5 HZ, C9-H), 7.95
(1H, t, J7.0 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.36 (1H, d,
J8.4 HZ, C9b-H), 2.25 (3H, s, NCH3), 1.62—3.20 (11H, rn,
CH2+CH), 100—1.50 (10H, rn, 5><CH2), 0.82 (3H, t, J6.9 HZ,
CH2CH3); 13C NMR (75 MHZ, CDCl3) 6157.0, 145.8,
144.8, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 31.8, 31.0,
29.7, 29.2, 29.1, 28.3, 26.4, 24.6, 22.7, 14.2.
EXAMPLE 7

20

25

iodide (BCN)
30

To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b

hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53
rnrnol) in AcOH (2 ml) Was added 1-iodononane (407 mg,

To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b
40

rnrnol) in AcOH (2 ml) Was added 1-iodoundecane (474 mg,
1.5 9 rnrnol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

45

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 116 mg (45%) of cis-6-dodecyl-1-rnethyl-2,3,3a,4,

5,9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide
(BCDD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.40

hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn
iodide (BCD)
55

hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53

(1H, d, J6.0 HZ, C7-H), 8.17 (1H, d, J7.8 HZ, C9-H), 7.94
(1H, t, J6.9 HZ, C8-H), 4.84 (2H, rn. pyCHZ), 3.31 (1H, d,
J8.4 HZ, C9b-H), 2.22 (3H, s, NCHB), 1.64—3.30 (11 H, In,
CH2+CH), 1.10—1.50 (18H, rn, 5><CH2), 0.82 (3H, t, J6.6 HZ,
CHZCHB); 13C NMR (75 MHZ, CDCl3) 6156.6, 145.7,
144.8, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 32.0, 31.0,
29.7><3, 29.6, 29.5, 29.4, 29.3, 28.4, 26.4, 24.6, 22.8, 14.2.
EXAMPLE 11

rnrnol) in AcOH (2 ml) Was added 1-iododecane (428 mg,

[3H]-DA Release Assay
60

Rat striatal slices (500 urn thickness, 6—8 mg Wet Weight)
Were incubated for 30 minutes in Kreb’s buffer (118 nM

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 106 mg (44%) of cis-6-decyl-1-rnethyl-2,3,3a,4,5,

9b-hexahydro-1H-pyrrolo[2,3f]isoquinolin-6-iurn iodide

(1H, d, J6.3 HZ, C7-H), 8.20 (1H, d, J7.5 HZ, C9-H), 7.93
(1H, t, J6.9 HZ, C8-H), 4.80 (2H, rn. pyCHZ), 3.38 (1H, d,

9b-hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53

Preparation of cis-6-Decyl-1-rnethyl-2,3,3a,4,5,9b

(BCD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.34

14.2.

iodide (BCDD)

EXAMPLE 8

1.5 9 rnrnol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

(1H, d, J6.3 HZ, C7-H), 8.19 (1H, d, J7.8 HZ, C9-H), 7.94
(1H, t, J6.9 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.34 (1H, d,
J8.4 HZ, C9b-H), 2.23 (3H, s, NCHB), 1.65—3.30 (11H, rn,
CH2+CH), 1.10—1.50 (16H, rn, 8><CH2), 0.82 (3H, t, J6.6 HZ,
CHZCHB); 13C NMR (75 MHZ, CDCl3) 6156.9, 145.9,
144.7, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 32.0, 31.0,
29.69, 29.65, 29.61, 29.5, 29.4, 29.2, 28.3, 26.4, 24.6, 22.8,

Preparation of cis-6-Dodecyl-1-rnethyl-2,3,3a,4,5,
35

(BCN) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.38

To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 90 mg (45%) of cis-1-rnethyl-6-undecyl-2,3,3a,4,

EXAMPLE 10

aqueous NaHCO3, Water and brine successively and dried.
Evaporation of the solvent folloWed by titration With ether
afforded 110 mg (47%) of cis-1-rnethyl-6-nonyl-2,3,3a,4,5,

(1H, d, J6.0 HZ, C7-H), 8.17 (1H, d, J7.5 HZ, C9-H), 7.93
(1H, t, J7.0 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.31 (1H, d,
J8.4 HZ, C9b-H), 2.24 (3H, s, NCHB), 1.62—3.20 (11H, rn,
CH2+CH), 1.10—1.50 (12H, rn, 6><CH2), 0.80 (3H, t, J6.6 HZ,
CH2CH3); 13C NMR (75 MHZ, CDCl3) 6156.9, 145.7,
144.6, 139.0, 125.2, 66.2, 58.9, 55.6, 40.6, 35.3, 31.8, 30.9,
29.7, 29.3, 29.2><2, 28.3, 26.3, 24.5, 22.7, 14.1.

1.29 rnrnol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

5,9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide

hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn

9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide

hexahydro-1H-pyrrolo[2,3-f]isoquinoline (80 mg, 0.43
rnrnol) in AcOH (2 ml) Was added 1-iodoundecane (361 mg,

(BCU) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.39

Preparation of cis-1-Methyl-6-nonyl-2,3,3a,4,5,9b

1.59 rnrnol). The mixture Was heated at re?ux under nitrogen
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated

9b-hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn

65

NaCl, 4.7 nM KCl, 1.2 nM MgCl2, 1.0 nM NaH2PO4, 1.3
nM CaCl2, 11.1 nM glucose, 25 nM NaHCO3, 0.1.1 nM
L-ascorbic acid, and 0.004 nM disodiurn EDTA; pH 7.4, and
saturated With 95% O2/5% CO2) in a metabolic shaker at 34°
C. Slices Were rinsed With 15 ml of fresh buffer and
incubated for an additional 30 minutes in fresh buffer

US 6,503,922 B2
11

12

containing 0.1 pM [3H]-DA (6 slices/3 ml). Subsequently,
slices Were rinsed With 15 ml of fresh buffer and transferred

TABLE 1

to a glass superfusion chamber. Slices Were superfused (1.0
ml/min) for 60 minutes With Kreb’s buffer containing

Comparative ICSUS for Syn and Anti Rotamer Analogs in the

S—(—)—NIC-evoked [3HlDA Release Assaya

nomifensine (10 pM and pargyline (10 pM) and maintained
at 34° C., pH 7.4, With continual aeration (95% O2/5% CO2).
TWo 5 minute samples (5 ml each) Were collected to
determine basal out?oW of [3H]-DA. N-Substituted confor
mationally restricted nicotine analogs Were added to the

10

superfusion buffer after the collection of the second sample
and remained in the buffer until 12 consecutive 5 minute

samples Were collected. Subsequently, S-(—)-nicotine (10
pM) Was added to the buffer and an additional 12 consecu

tive ?ve minute samples Were collected. At the end of the
experiment, each slice Was solubiliZed and the [3H] content
of the tissue determined.

Radioactivity in the superfusate and tissue samples Was
determined by liquid scintillation spectroscopy. Fractional

15

20

release for each tritium collected in each sample by the total
tritium present in the tissue at the time of sample collection
and Was expressed as a percentage of total tritium. Basal

[3H]out?oW Was calculated from the average of the tritium
collected in the tWo ?ve minute samples just before addition
of the conformationally restricted nicotine analog. The sum
of the increase in collected tritium resulting from either

25

exposure to the test compound or exposure to nicotine in the

absence and presence of the test compound equaled total

30

[3H]over?oW. [3H]Over?oW Was calculated by subtracting
the [3H]out?oW during an equivalent period of prestimula
tion from the values in samples collected during and after
drug exposure. Inasmuch as the radiolabelled compounds
Were not separated and identi?ed, the tritium collected in
superfusate is referred to as either [3H]out?oW or [3H]

35

3No signi?cant intrinsic agonist activity Was observed for any of these
compounds in this assay beloW 10 ,uM.

over?oW, rather than as [3H]-DA. [3H]Over?oW primarily
represents [3H]-DA in the presence of nomifensine and
pargyline in the superfusion buffer.

EXAMPLE 12
40

Striata from tWo rats Were dissected, pooled, and homog
eniZed With a Tekmar polytron in 10 vol of ice-cold modi?ed

The conformationally restricted nicotine analogs Were
evaluated for their ability to evoke [3H] release from rat
striatal slices at tWo concentrations (0.1 and 1 pM). In

addition, the classical competitive nicotinic antagonist

45

None of the compounds examined had any signi?cant [3H]
DA releasing properties in this assay at concentrations beloW
10 pM, but all the compounds exhibited intrinsic activity at
10 pM Since striatal NIC-evoked [3H]-DA: release is
thought to be mediated through a mechanism involving the

(x3[32-containing receptor subtype, these compounds do not
possess signi?cant agonist activity beloW 10 pM at this

resuspension, incubation, and centrifugation Was repeated.
55

and stored at —40° C. until assayed. Upon assay, the pellet

Were also evaluated for their ability to inhibit NIC evoked

[3H]-DA release. In these experiments, the striatal slices

60

of the analogs prior to NIC (10 pM) exposure. Antagonist
activity Was evaluated by comparing the NIC-evoked [3H]

MilliQ Water Which provided for approximately 200 pg
protein per 100 pl aliquot. Competition assays Were per
formed in triplicate in a ?nal volume of 200 pl Krebs
HEPES buffer containing 250 mmol Tris buffer (pH 7.5 at 4°
C.). Reactions Were initiated by addition of 100 pl of

over?oW in the absence and presence of the analogs. The

potency of these bridged NONI analogs for inhibition of
NIC-evoked [3H]-DA release from rat striatal slices is
illustrated in Table 1 by a comparison of their IC5O values.

The pellet Was froZen under fresh 10% Krebs-HEPES buffer

Was resuspended in the Krebs-HEPES buffer, incubated at
37° C. for 5 minutes, and centrifuged at 15,000 g for 20
minutes. The ?nal pellet Was resuspended in 3.6 ml ice-cold

The conformationally restricted bridged NONI analogs

Were superfused for 60 minutes With various concentrations

Krebs-HEPES buffer (20 mM HEPES, 118 mM NaCl, 4.8
mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH
7.5). The homogenates Were incubated at 37° C. for 5
minutes and centrifuged at 15,000 g for 20 minutes. The
pellet Was resuspended in 10 volumes of ice-cold MilliQ
Water, incubated for 5 minutes at 37° C., and centrifuged at
15,000 g for 20 minutes. The second pellet Was then
resuspended in 10 volumes of fresh ice-cold 10% Krebs
HEPES buffer, incubated at 37° C., and centrifuged at
15,000 g for 20 minutes. The latter sequence of

DHBE Was also examined in this assay for comparison.

putative receptor subtype.

[3H]-NIC Binding Assay

65

membrane suspension to 3 mM [3H]-NIC (50 pl). and one of
at least nine concentrations of analog (50 pl). After a 90
minutes incubation at 40° C., reactions Were terminated by

US 6,503,922 B2
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14

dilution of the samples With 3 ml of ice-cold Krebs-HEPES

CaCl2 and 0.1 mM MgSO4, pH=7.5). The homogenate Was

buffer followed immediately by ?ltration through Whatman
GF/B. glass ?ber ?lters (presoaked in 0.5%

cocktail (Research Products International Corp., Mt.

incubated at 37° C. for 10 minutes and centrifuged at
25,000><g for 15 minutes at 40° C. The pellet Was Washed 3
times more by resuspension in the 20 volumes of the same
buffer and centrifugation at the above parameters. The ?nal
pellet Was stored at —20° C. under 4.6 ml of the incubation
buffer and Was suspended just before the incubation With

Prospect, Ill.) added. Nonspeci?c binding determined in

radioligand.

polyethyleneimine) using a Brandel Cell Harvester. Filters
Were rinsed three times With. 3 ml of ice-cold Krebs-HEPES

buffer, transferred to scintillation vials, and 5 ml scintillation
triplicate Was de?ned as binding in the presence of 10 pM
NIC. Binding parameters Were determined using the

10

Weighted, least squares regression.

Was measured using a modi?cation of the method of Davies

The conformationally restricted nicotine analogs Were

et al., “Characterisation of the binding of [3H]
methyllycaconitine: a neW radioligand for labelling ot7-type

evaluated for their ability to displace [3H]-NIC binding from
rat striatal membranes. The results are summariZed in Table

2. Furthermore, the displacement by the analogs Was com

15

pared to those produced by NONI, NDNI, and DHBE. All of

UK. Binding Was performed in duplicate, in a ?nal volume

much loWer af?nities than DHBE. The 8-carbon alkyl chain
20

pounds and 2.5 mM [3H]-MLA (?nal concentration) and
25

30

Speci?c Binding of [3H]—NIC to Rat Striatal Nicotinic Acetylcholine
Concentration (MM)a

NONI
NDNI
DHBE
ACO
ACN
ACD
ACU
ACDD
BCO
BCN
BCD
BCU
BCDD

42.0
42.0
55.0
43.4
51.2
50.9
47.1
44.7
51.2
48.0
53.7
53.7
45.8

r
r
r
r
r
r
r
r
r
r
r
r
r

1
3.0
3.3
3.0
1.0
2.9
2.7
2.1
1.7
1.5
2.9
0.5
0.5
3.9

42.6
9.2
18.0
44.5
49.8
50.3
51.3
49.5
50.5
49.6
54.9
56.1
43.7

r
r
r
r
r
r
r
r
r
r
r
r
r

10
2.6
1.0
5.0
0.4
3.6
3.7
2.0
0.7
1.2
1.2
0.7
0.6
4.5

37.5
0.5
4.0
42.2
48.9
52.1
49.0
49.8
39.7
47.7
54.4
53.9
43.0

r
r
r
r
r
r
r
r
r
r
r
r
r

100
2.3
0.2
1.0
0.5
2.9
2.6
0.3
2.9
1.4
2.1
1.1
1.2
4.7

14.0 r 1.3
NDb
ND
30.2 r 6.9
30.2 r 2.2
37.0 r 1.7
42.7 r 2.1
44.5 r 1.7
13.5 r 0.5
36.2 r 0.3
47.9 r 2.8
37.3 r 1.8
34.0 r 2.1

35

measured using the Bradford dye-binding procedure With
bovine serum albumin as the standard.

In order to determine if these compounds have selectivity

at the (x362 receptor subtype, the bridged NONI analogs
Were evaluated for their ability to displace [3H]-MLA bind
40

ing from rat brain membranes, as a re?ection of their

interaction With the (x7 receptor (Table 3). In addition, the
classical (x7 receptor antagonist ot-bungarotoxin Was also
examined in this assay for comparison. ot-Bungarotoxin
afforded a Ki value of 28.615 .4 nM in the above assay. The
45

results from the competition binding assay shoWed that none

of the conformationally constrained compounds possessed
any signi?cant binding af?nity in the [3H]-MLA assay. The

3Data are expressed as fmol/mg of protein, mean : S.E.M of 3 indepen

dent experiments. Speci?c binding is calculated as the difference between
the total binding of 3 nM [3H]—NIC to the receptors alone and its nonspe
ci?c binding in the presence of 10 ,uM cold nicotine.
bND: Not determined.

folloWed by immediate ?ltration through presoaked in 0.5%

polyetylenimine glass ?ber ?lters (S&S, grade #32) using a
Brandel harvester system. Filters Were rinsed three times
With 3 ml of ice-cold buffer, transferred to scintillation vials
and 4 ml of scintillation cocktail Was added. Protein Was

Receptors in the Presence of Conformationally Constrained NONI Analogs

0

incubated for 2 hours at room temperature. Total binding
Was measured in the absence of unlabelled ligand and

nonspeci?c binding Was determined in the presence of 1 pM
unlabelled MLA. The binding reaction Was terminated by
dilution of samples With 3 ml of ice-cold incubation buffer

TABLE 2

Compound

of 250 pl of the incubation medium, containing 20 mM
HEPES, 144 mM NaCI, 1.5 mM KCl, 2 mM CaCI2, 1 mM
MgSO4 and 0.05% BSA, pH=7.5. Reaction Was initiated by
the addition of 100 pl of membrane suspension to the
samples containing a desired concentration t of test com

interact With this binding site compared to the high affinity
of NDNI. Thus, the unique conformationally restricted ste

reochemistry presented by these analogs to the (x462
containing receptor subtype is not recogniZed by this sub
type.

neuronal nicotinic acetylcholine receptors,’

Neuropharmacology, 38, 679—690 (1999). [3H]-MLA (25.4
Ci/mmol) Was purchased from Tocris Cookson Ltd., Bristol,

the compounds examined displaced [3H]-NIC binding With
bridged nicotinium compounds (ACO and BCO) had much
loWer affinity for the [3H]-NIC binding site compared to
NONI; surprisingly, the 10-carbon alkyl chain bridged nico
tiniumr compounds (ACD and BCD) lost their ability to

The binding of [3H]methyllycaconitine ([3H]MLA) to
probe ot7-type neuronal nicotinic acetylcholine receptors

percentage control of 2.5 nM [3H]-MLA binding to the rat
brain membrane preparation in the presence of 10 pM of
50

bridged NONI analogs ranged from 92.3 to 101.9, indicating
that at a 10 pM concentration, the above compounds had no

signi?cant af?nity for the (X7 receptor subtype.
EXAMPLE 13

[3H]-MLA Binding Assay

TABLE 3
55

[3H]—MLA Binding in the Presence of Conformationally

Na'ive male Sprague-DaWley rats Weighing 220—250 g

Restrained NONI and NDNI Analogs

Were housed tWo per cage With free access to food and Water.

All procedures in these studies Were approved by the Insti
tutional Animal Care and Use Committee at the University
of Kentucky. The animals Were killed by decapitation, each
brain Was quickly removed and placed on ice-cold glass
platform. The brain Was dissected into the Whole brain tissue
Without cortex, striatum and cerebellum and Was froZen in
liquid nitrogen and stored at —70° C. until use.
The brain tissue Was homogeniZed With a Tekmar Poly

tron (setting 40) in 20 volumes of ice-cold hypotonic buffer
(2 mM HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM

Compound
60

65

ACO
ACN
ACD
ACU
ACDD
BCO
BCN
BCD

% Control [3H]-MLA
Binding at 10 ,uM"
91.5
100.7
101.9
100.4
101.9
93.6
94.0
96.2

US 6,503,922 B2
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substituted alkenyl, alkynyl, substituted alkynyl, aryl,
substituted aryl, aryloXy, arylamino, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub
stituted arylalkynyl, heterocyclic, substituted heterocy

TABLE 3-continued
[3H]—MLA Binding in the Presence of Conformationally
Restrained NONI and NDNI Analogs

Compound
BCU
BCDD

clic or tri?uoromethyl, provided, however, that the
carbonyl functionality is not conjugated With an alkenyl
or alkynyl functionality; OY4 or N(Y“)2 Wherein Y4 is

% Control [3H]-MLA
Binding at 10 ,uM"

hydrogen, alkyl, substituted alkyl, cycloalkyl, substi
tuted cycloalkyl, alkenyl, subtituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl,
substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub
stituted arylalkynyl, heterocyclic, substituted
heterocyclic, acyl, tri?uoromethyl, alkylsulfonyl or

92.3
94.2

*Data are expressed as % Whole brain binding relative to control (2.5 nM

[3H]-MLA).
The purpose of the above description and examples is to
illustrate some embodiments of the present invention With
out implying any limitation. It Will be apparent to those of
skill in the art that various modi?cations and variations may

15

arylsulfonyl, provided that the OY4 or N(Y“)2 func
tionality is not conjugated With an alkenyl or alkynyl

functionality; SY5 Wherein Y5 is hydrogen, alkyl, sub
stituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, subtituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, alkylaryl, substituted

be made to the composition and method of the present
invention Without departing from the spirit or scope of the
invention. All patents and publications cited herein are

incorporated by reference in their entireties.

alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,

We claim:

substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, substituted heterocyclic or
tri?uoromethyl, provided that the SY5 functionality is

1. A compound of the following III or IV;
III

25

not conjugated With an alkenyl or alkynyl functionality;

R6 represents alkyl, substituted alkyl, cycloalkyl, substi
tuted cycloalkyl, alkenyl, subtituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted
arylalkenyl, arylalkynyl, substituted arylalkynyl, het
erocyclic or substituted heterocyclic; and

X represents chlorine, bromine, iodine, HSO4, 1/2SO2,
2. The compound according to claim 1, Wherein R1 is
35

C1—C1Oalkyl.
3. The compound according to claim 1, Wherein R1

C1—C6alkyl.
4. The compound according to claim 1, Wherein R1

methyl.
5. The compound according to claim 1, Wherein R1

ethyl.
6. The compound according to claim 1, Wherein R1

isopropyl.
7. The compound according to claim 1, Wherein R1

isobutyl.
45

8. The compound according to claim 1, Wherein R2 is

hydrogen.
9. The compound according to claim 1, Wherein R3, R4
and R5 are individually selected from hydrogen, halogen,
alkyl, or alkanoyl.
10. The compound according to claim 1, Wherein R6 is a

Wherein

A and B each independently represent CH2 or CHZCHZ;
R1 represents hydrogen, loWer alkyl or an aromatic group

containing species;

C4—C19 unbranched alkyl.
11. The compound according to claim 1, Wherein X is

R2 represents hydrogen or loWer alkyl;

R3, R4 and R5 each independently represent hydrogen;
alkyl; substituted alkyl; cycloalkyl; substituted
cycloalkyl; alkenyl; substituted alkenyl; alkynyl; sub
stituted alkynyl; aryl; substituted aryl; alkylaryl; sub
stituted alkylaryl; arylalkyl; substituted arylalkyl; ary
lalkenyl; substituted arylalkenyl; arylalkynyl;

iodine.

12. The compound according to claim 1, Wherein said
55

compound is cis-1-methyl-8-octyl-2,3,3a,4,5,9b-hexahydro
1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACO).
13. The compound according to claim 1, Wherein said

compound is cis-1-methyl-8-nonyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

substituted arylalkynyl; heterocyclic; substituted het

(ACN).

erocyclic; tri?uoromethyl; halogen; cyano; nitro; S(O)
Y2, S(O)2Y2, S(O)2OY2 or S(O)2NHY2, Wherein each

14. The compound according to claim 1, Wherein said

compound is cis-8-decyl-1-methyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

Y2 is hydrogen, loWer alkyl, alkenyl, alkynyl or aryl,
provided that When R3, R4 or R5 is S(O)Y2, Y2 is not
hydrogen, and further provided that When Y2 is alkenyl

(ACD).
15. The compound according to claim 1, Wherein said

With a heteroatom; C(O)Y3, Wherein Y3 is hydrogen,

compound is cis-1-methyl-8-undecyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

alkyl, substituted alkyl, alkoXy, alkylamino, alkenyl,

(ACU).

or alkynyl, the site of unsaturation is not conjugated

65
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16. The compound according to claim 1, wherein said

27. A method of binding a nicotine receptor With a

compound according to claim 1, Wherein said compound

compound is cis-8-dodecyl-1-methyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide

inhibits [3]-NIC binding.
28. A method of inhibiting the binding of a nicotinic

(ACDD).

receptor comprising the step of administering of a pharma

17. The compound according to claim 1, Wherein said

compound is cis-1-methyl-6-octyl-2,3,3a,4,5,9b-heXahydro
1H-pyrrolo[2,3-f]isoquinolin-8-ium iodide (BCO).
18. The compound according to claim 1, Wherein said

compound is cis-1-methyl-6-nonyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide

10

(BCN).

19. The compound according to claim 1, Wherein said

compound is cis-6-decyl-1-methyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide

(BCD).

15

20. The compound according to claim 1, Wherein said

compound is cis-1-methyl-6-undecyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide

ceutically effective amount of a compound according to
claim 1.
29. A method of treating abuse of nicotinic receptor
agonists, addiction to tobacco products, or addiction to
nicotine comprising the step of administering an effective
amount of a compound according to claim 1.
30. A method of treating AlZheimer’s disease comprising
the step of administering of a pharmaceutically effective
amount of a compound according to claim 1.
31. A method of treating Parkinson’s disease comprising
the step of administering of a pharmaceutically effective
amount of a compound according to claim 1.

32. A method of treating pain, comprising the step of
administering of a pharmaceutically effective amount of a

(BCU).

compound according to claim 1.

21. The compound according to claim 1, Wherein said

33. A method of binding a nicotine receptor With a

compound is cis-6-dodecyl-1-methyl-2,3,3a,4,5,9b
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide

compound according to claim 1, Wherein said compound

(BCDD).

tinic receptor agonists.

competitively inhibits central nervous system acting nico

22. A compound according to claim 1, Wherein the ring
junction betWeen a and b rings is cis or trans.

23. A compound according to claim 1, Wherein said

compound is substantially optically pure.
24. A compound according to claim 1, Wherein said
compound is a racemic mixture or a diastereometric mixture.

25. A method of binding a nicotine receptor With a

34. A method of binding a nicotine receptor With a
25

compound according to claim 1, Wherein said compound
acts at the putative (x362 neuronal nicotinic receptor in the
central nervous system.

35. A method of treating irritable boWel syndrome, com

prising the step of administering of a pharmaceutically
effective amount of a compound according to claim 1.

compound according to claim 1, Wherein said compound is

36. A method of treating calitis, comprising the step of

a nicotinic receptor antagonist.
26. A method of binding a nicotine receptor With a

administering of a pharmaceutically effective amount of a

compound according to claim 1, Wherein said compound
inhibits NIC-evoked [3H]-DA release.

compound according to claim 1.
*
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